EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Thieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets

Anvarjon Buronov iD, Shukhrat Gaybullaev iD, Zarifa Murtazaeva, Feruza Ruzieva, Zohidjon Khushnazarov, Davron Turgunov, Azizbek Nasrullaev, Rustamkhon Kuryazov, Yuldash Takhirov iD, Firdavsi Tursunov, Temur Kushatov, Dilshod Dushamov iD und 11 weitere

International Journal of Molecular Sciences · 20.08.2026 · 27 (16) · 7457

DOI: 10.3390/ijms27167457 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.08.2026. Verfasst von Anvarjon Buronov und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Institute of Biochemistry, Samarkand State University, University Blvd. 15, Samarkand 140104, Uzbekistan. Hauptthemen laut MEDLINE: Pyrimidines, Antineoplastic Agents, Drug Discovery, Drug Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Organization of the Laboratory for the Creation of anticancer drugs, Xinjiang International Science & Technology Cooperation Key Program, Xinjiang International Science & Technology Cooperation Key Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The thieno[3,2-d]pyrimidine scaffolds have emerged as an important class of heterocycles in anticancer drug discovery, with clinically advanced drugs olmutinib and pictilisib highlighting their therapeutic potential. This review presents thieno[3,2-d]pyrimidine-containing anticancer agents reported between January 2008 and August 2025, focusing on synthetic methodologies, anticancer-related biological activities, and structure–activity relationships. Thieno[3,2-d]pyrimidine derivatives have been investigated as inhibitors of numerous cancer-related targets, including EGFR, PI3K/mTOR, CDKs, JAK, VEGFR, HDAC, ATR, and other oncogenic proteins. This review also summarizes thieno[3,2-d]pyrimidine scaffolds with anticancer activity, with particular emphasis on the design and synthesis of lead compounds, molecular hybridization strategies, and recent advances in this area. Synthetic pathways for lead compounds are systematically presented and discussed, along with pharmacophoric features. In addition, detailed structure–activity relationship analyses are provided to highlight the influence of heterocyclic fusion, linker optimization, hydrogen-bonding motifs, electronic effects, hydrophobic fragments, and the introduction of hybrid scaffolds on antiproliferative potency, kinase inhibition, selectivity, and multitarget activity. In addition, this review demonstrates the significant potential of thieno[3,2-d]pyrimidine-based scaffolds as a privileged platform for the development of next-generation targeted anticancer agents and offers valuable guidance for future medicinal chemistry research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesAntineoplastic AgentsDrug DiscoveryDrug DesignNeoplasmsHumansStructure-Activity RelationshipAnimals

Stichwörter der Autor:innen

CDK inhibitorsEGFR inhibitorsPI3K/mTOR inhibitorsanticancer agentsdual-target inhibitorsolmutinibpictilisibstructure–activity relationshipthieno [3,2-d]pyrimidinesthiophene

Substanzen

PyrimidinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Institute of Biochemistry, Samarkand State University, University Blvd. 15, Samarkand 140104, Uzbekistan.
  • Department of Chemistry, Urgench State University named after Abu Rayhan Biruni, Kh. Olimjon st. 14, Urgench 220100, Uzbekistan.
  • Samarkand State Medical University, Amir Temur st. 18, Samarkand 140100, Uzbekistan.
  • Scientific and Practical Center of Immunology, Allergology and Human Genomics, Samarkand State Medical University, Makhdūm-i A'ẓam st. 18, Samarkand 140104, Uzbekistan.
  • Research Institution "Chinese-Tajik Innovation Center for Natural Products", National Academy of Sciences of Tajikistan, Dushanbe 734063, Tajikistan.
  • State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, South Beijing Rd 40-1, Urumqi 830011, China.

ORCID-Profile: Anvarjon Buronov, Shukhrat Gaybullaev, Yuldash Takhirov, Dilshod Dushamov, Sodik Numonov, Chao Niu, Zhishen Ge, Khurshed Bozorov

Förderung

  • Organization of the Laboratory for the Creation of anticancer drugs
  • Xinjiang International Science & Technology Cooperation Key Program
  • Xinjiang International Science & Technology Cooperation Key Program

Zitieren

APA

Buronov, A., Gaybullaev, S., Murtazaeva, Z., Ruzieva, F., Khushnazarov, Z., Turgunov, D., Nasrullaev, A., Kuryazov, R., Takhirov, Y., Tursunov, F., Kushatov, T., Dushamov, D., Matmuratov, S., Nurullaeva, N., Shodikulova, A., Khalikov, K., Kholmurodova, D., Numonov, S., Niu, C., …, & Bozorov, K. (2026). Thieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets. International Journal of Molecular Sciences, 27(16), 7457. https://doi.org/10.3390/ijms27167457

Vancouver

Buronov A, Gaybullaev S, Murtazaeva Z, Ruzieva F, Khushnazarov Z, Turgunov D, et al. Thieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets. International Journal of Molecular Sciences. 2026;27(16):7457. doi:10.3390/ijms27167457

BibTeX
@article{Buronov2026,
  author = {Buronov, Anvarjon and Gaybullaev, Shukhrat and Murtazaeva, Zarifa and Ruzieva, Feruza and Khushnazarov, Zohidjon and Turgunov, Davron and Nasrullaev, Azizbek and Kuryazov, Rustamkhon and Takhirov, Yuldash and Tursunov, Firdavsi and Kushatov, Temur and Dushamov, Dilshod and Matmuratov, Shavkat and Nurullaeva, Nilufar and Shodikulova, Aziza and Khalikov, Kakhor and Kholmurodova, Dilafruz and Numonov, Sodik and Niu, Chao and Ji, Yuanyuan and Zhao, Jiangyu and Ge, Zhishen and Bozorov, Khurshed},
  title = {Thieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7457},
  doi = {10.3390/ijms27167457}
}
Kostenlos starten →